Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Key Points

• CFO Ivan Hyep sold 12,500 Bicara shares for approximately $349,625 under a pre-arranged Rule 10b5-1 plan, reducing his direct holdings by 8.78% to 129,855 shares.
• Bicara’s stock rose 3.7% to $24.63, while its second-quarter loss of $0.82 per share matched analyst expectations. The company is expected to report a full-year loss of $3.42 per share.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $32.73; recent targets include $39 from Morgan Stanley and Wedbush’s $33.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 12,500 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the sale, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,632,044.35. The trade was a 8.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, July 8th, Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.85, for a total value of $807,800.00.
• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.42, for a total value of $187,864.00.

Bicara Therapeutics Stock Up 3.7%

NASDAQ BCAX traded up $0.87 on Wednesday, hitting $24.63. The company's stock had a trading volume of 810,259 shares, compared to its average volume of 608,476. The firm has a market cap of $1.62 billion, a PE ratio of -8.86 and a beta of -0.75. Bicara Therapeutics Inc. has a 1-year low of $10.30 and a 1-year high of $30.99. The company's 50-day moving average is $25.90 and its 200 day moving average is $21.69.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting the consensus estimate of ($0.82). On average, equities analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Guggenheim assumed coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They issued a "buy" rating and a $42.00 price target for the company. Morgan Stanley lifted their price objective on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an "overweight" rating in a report on Tuesday. Wedbush increased their price objective on Bicara Therapeutics from $30.00 to $33.00 and gave the stock an "outperform" rating in a research note on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Finally, Wells Fargo & Company increased their target price on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an "equal weight" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $32.73.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently modified their holdings of BCAX. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock valued at $44,000 after purchasing an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics during the fourth quarter valued at about $45,000. Larson Financial Group LLC increased its holdings in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after buying an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after acquiring an additional 4,585 shares during the last quarter.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported a second-quarter loss of $0.82 per share, described as narrower than expected and matching the cited analyst consensus. The result helped support the view that the company is maintaining financial discipline while advancing its pipeline. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: The company said enrollment in its pivotal cancer study is progressing and remains on track for completion in 2026. Wedbush viewed the enrollment timeline as a positive catalyst for BCAX’s clinical program. Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on expectations for Bicara’s clinical and commercial prospects. Benzinga
• Positive Sentiment: Recent commentary remains constructive despite broader market headwinds, with optimism centered on the company’s pipeline progress and upcoming clinical milestones. Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
• Neutral Sentiment: Bicara also announced strategic leadership transitions intended to support its next phase of execution and growth. The changes may improve operational focus, but they introduce an element of transition risk. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Wells Fargo raised its price target from $16 to $23 but retained an Equal Weight rating. Its target remains below the referenced trading level, signaling a more cautious view than BTIG’s forecast. Benzinga

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source